News | Breast Imaging | October 01, 2015

Hologic Displays Latest Women’s Health Technologies at RSNA 2015

hologic mammography Selin

October 1, 2015 — The recent KLAS Research women’s imaging report, Women's Imaging 2015. Are New Technologies Delivering Promised Benefits?, notes that Hologic is the undisputed industry leader in mammography and the vendor said it hopes to hold that position. At RSNA 2015, Hologic is featuring a growing family products. At RSNA 2015, the vendor said they expect huge interest to continue in breast tomosynthesis (3-D breastr imaging) offerings. Sixty-five percent of the U.S. mammography providers surveyed by KLAS planned to invest in breast tomosynthesis technology during the next two years, up from 57 percent in 2014 (for more data).

Tomosynthesis continues as a hot topic in the radiology world. Last year, breast tomosynthesis continued its remarkable run by winning the award for Hottest Clinical Procedure by AuntMinnie readers and editors for the fifth straight year. The sustained interest in the technology is being driven by a steady stream of research papers on the technology's positive clinical impact, particularly on breast screening. There are over 60 papers, poster sessions and lectures on breast tomosynthesis listed in the RSNA program this year. 

In the past year, Hologic launched a number of new products to build on our breast tomosynthesis franchise. Five examples include:

Genius 3D Mammography Exams
A Genius 3D Mammography exam is available only on our Selenia Dimensions system. The Genius 3D Mammography exams are proven clinically superior to conventional mammography. Genius exams are helping find breast cancers earlier, while reducing recall rates and false positives. More than 8 million women in the United States have benefited from this breakthrough exam. Genius exams deliver advantages, not only for the women who benefit from early detection, but also for the physicians who care for them and the facilities that offer this lifesaving technology.

C-View Generated 2-D Images From Selenia Dimensions Tomosynthesis Data Sets
The C-View software is designed to generate 2-D images from Genius 3D Mammography image slices, eliminating the need for a separate 2-D exam. The technology benefits, including a reduction in X-ray exposures leading to shorter exam times (less than four second scan per view), and increased patient comfort from the shorter compression time. Published studies including a number of new papers accepted for presentation at RSNA have shown that the use of C-View software results in a clinically superior exam at virtually the same low radiation dose as a conventional 2-D screening exam.

Affirm Tomosynthesis Guided Breast Biopsy
The Affirm 3D-guided breast biopsy product saw huge interest in 2015. This first-of-its-kind technology is designed for the localization and accurate targeting of regions of interest and is especially important for targeting lesions not detected in 2-D imaging, or when using other modalities. To date, Hologic is the only company with a tomosynthesis guided breast biopsy option. Affirm is designed to provide numerous advantages over traditional stereotactic biopsy procedures, including faster lesion targeting and reduced patient procedure time. 

I-View Contrast Enhanced 2-D Mammography and Tomosynthesis Fusion
Using an iodinated contrast agent, the I-View software on the Hologic Selenia Dimensions system enables users to image the functional 2-D contrast uptake and the morphological Genius 3D Mammography image in rapid sequence and combine these two image sets into a single fused study. In the fused study, the 2-D contrast image can identify potential lesions based on their physiological state due to an increase in the contrast agent uptake. The Genius 3D Mammography image can then be overlaid on the 2-D contrast image and provide morphological information on the lesion, such as improved visibility of associated spiculations.

I-View dual modality contrast enhanced imaging is designed to confirm findings and localize lesions when breast cancer imaging results are inconclusive. A contrast enhanced exam using I-View software can be performed in less than 10 minutes, in the same exam room, and on thesame popular screening equipment. 

The I-View imaging mode is designed to offer several advantages over conventional contrast breast MRI:

•    Reduced cost.
•    Contrast imaging availability to patients for whom MRI is contraindicated.
•    Access to patients in areas where MRI systems are not available.

I-View  imaging software is an extension of the existing indication for diagnostic imaging with the Hologic Selenia Dimensions system. The product is 510(k) cleared and CE marked.

Quantra Breast Density Assessment For Breast Tomosynthesis 
Quantra v2.1 software is FDA-cleared and compatible for breast tomosynthesis. It features the latest advances in density assessment algorithms, a newly designed, and easy to read Secondary Capture display using BI-RADS fifth edition terminology and user-friendly naming for all Quantra assessed values.

Hologic is also showing other products – from biopsy devices and targeted radiation therapy, to Fluoroscan mini C-arms and new uses for our Horizon bone densitometry systems. Three examples of other products being showing from the interventional solutions business at RSNA include:

Sertera Spring Loaded Biopsy Device 
The newest member of Hologic’s ultrasound-guided breast biopsy family, is a disposable, core needle biopsy device available in multiple gauge sizes. The device is lightweight and designed to be completely armed and fired with one hand for core needle biopsies.

Brevera Breast Biopsy System With CorLumina Imaging Technology
An advanced biopsy platform designed to increase clinical confidence, reduce procedure times and improve the patient experience. 

New Prone Biopsy System
Our new prone biopsy system is a fully redesigned dedicated prone biopsy solution. The prone table uses the latest mammography imaging technology including 3-D imaging. It is designed to make it fast and easy to identify and confidently target lesions, especially those found only using the Genius 3D Mammography exam.

For more information: www.hologic.com

 

Related Content

Fujifilm Installing New DR Equipment for Three Large Healthcare Systems
News | Digital Radiography (DR) | September 22, 2017
Fujifilm Medical Systems U.S.A. Inc. recently closed new contracts to enhance diagnostic imaging capabilities for...
Theraclion to Launch Metastatic Breast Cancer Trial Combining Echotherapy and Immunotherapy
News | Focused Ultrasound Therapy | September 18, 2017
September 18, 2017 — Theraclion and co-lead investigator David Brenin, M.D., from the University of Virginia School o
DenseBreast-info.org Debuts  Spanish Language Video  About Dense Breasts
News | Breast Density | September 12, 2017
Breast cancer risks associated with breast density are the subject of a new Spanish language video launched recently by...
Asian Study Underlines Potential Value of Pressure-Guided Mammography
News | Mammography | September 11, 2017
Sigmascreening recently announced that a study of in total 15,898 in digital mammograms from 3,772 Asian women...
Delphinus Enrolls First Patient in Discover Breast Ultrasound Clinical Project
News | Ultrasound Womens Healthcare | September 08, 2017
September 8, 2017 — Delphinus Medical Technologies Inc.
Breast imaging X-ray mammogram showing a breast tumor. Photo courtesy of Monthian Ritchan-Ad

Photo courtesy of Monthian Ritchan-Ad

Feature | Breast Density | September 08, 2017 | By Roy Prager, M.D.
While mammograms play a vital role in efforts to identify breast cancer, they can present some challenges in women with...
FDA Clears Senographe Pristina Mammography System With Patient-Assisted Compression
Technology | Mammography | September 05, 2017
The U.S. Food and Drug Administration (FDA) cleared GE Healthcare’s Senographe Pristina with Self-Compression, the...
FDA Releases Six-Month Inspection Data From EQUIP Mammography Quality Initiative
News | Mammography | September 01, 2017
September 1, 2017 — The Division of Mammography Quality Standards (DMQS) of the U.S.
Hologic Announces Availability of Brevera Breast Biopsy System With CorLumina Imaging Technology
Technology | Breast Biopsy Systems | August 31, 2017
Hologic Inc. announced U.S. commercial availability of the Brevera breast biopsy system with CorLumina imaging...
China FDA Approves Xoft Axxent Balloon Applicators for Early-Stage Breast Cancer
News | Brachytherapy Systems, Women's Healthcare | August 30, 2017
iCAD Inc. announced that the company’s Xoft Axxent balloon applicators have received approval from the China Food...
Overlay Init